Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27932229

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2017 Jan 7
First author
Bruix J

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2017 Jan 7;389(10064):4-6. doi: 10.1016/S0140-6736(16)32480-1.
    note
    Source null
    related pmid
    27932228
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2017 Feb;14(2):70-71. doi: 10.1038/nrclinonc.2016.214.
    note
    Source null
    related pmid
    27995948
    relationship
    Comment in
  3. citation
    Lancet. 2017 Jan 7;389(10064):36. doi: 10.1016/S0140-6736(16)32615-0.
    note
    Source null
    related pmid
    28091376
    relationship
    Erratum in
  4. citation
    Nat Rev Gastroenterol Hepatol. 2017 Mar;14(3):141-142. doi: 10.1038/nrgastro.2017.7.
    note
    Source null
    related pmid
    28174418
    relationship
    Comment in
  5. citation
    Z Gastroenterol. 2017 Jul;55(7):685-686. doi: 10.1055/s-0043-106861.
    note
    Source null
    related pmid
    28437801
    relationship
    Comment in
  6. citation
    Dig Liver Dis. 2017 Aug;49(8):943-944. doi: 10.1016/j.dld.2017.04.022.
    note
    Source null
    related pmid
    28546063
    relationship
    Comment in

Authors and identifiers

  1. name
    Bruix J
    type
    Author
  2. name
    Qin S
    type
    Author
  3. name
    Merle P
    type
    Author
  4. name
    Granito A
    type
    Author
  5. name
    Huang YH
    type
    Author
  6. name
    Bodoky G
    type
    Author
  7. name
    Pracht M
    type
    Author
  8. name
    Yokosuka O
    type
    Author
  9. name
    Rosmorduc O
    type
    Author
  10. name
    Breder V
    type
    Author
  11. name
    Gerolami R
    type
    Author
  12. name
    Masi G
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Bruix J
    type
    Author
  2. name
    Qin S
    type
    Author
  3. name
    Merle P
    type
    Author
  4. name
    Granito A
    type
    Author
  5. name
    Huang YH
    type
    Author
  6. name
    Bodoky G
    type
    Author
  7. name
    Pracht M
    type
    Author
  8. name
    Yokosuka O
    type
    Author
  9. name
    Rosmorduc O
    type
    Author
  10. name
    Breder V
    type
    Author
  11. name
    Gerolami R
    type
    Author
  12. name
    Masi G
    type
    Author
bibliography ids
  1. nci-bib-e7c761c858ec635e72ade2ff
book metadata
content sha256
74dd98aee37f2da68fad490e103f59319bc61d2ee1a7d9616d673f7df385b536
document type
citation
dois
  1. 10.1016/S0140-6736(16)32453-9
electronic publication date
display
2016 Dec 6
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27932229
immutable id
pubmed:27932229@74dd98aee37f2da68fad490e103f59319bc61d2ee1a7d9616d673f7df385b536
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10064
name
Lancet (London, England)
nlm unique id
2985213R
pages
56-66
volume
389
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2017 Jan 7;389(10064):4-6. doi: 10.1016/S0140-6736(16)32480-1.
    note
    Source null
    related pmid
    27932228
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2017 Feb;14(2):70-71. doi: 10.1038/nrclinonc.2016.214.
    note
    Source null
    related pmid
    27995948
    relationship
    Comment in
  3. citation
    Lancet. 2017 Jan 7;389(10064):36. doi: 10.1016/S0140-6736(16)32615-0.
    note
    Source null
    related pmid
    28091376
    relationship
    Erratum in
  4. citation
    Nat Rev Gastroenterol Hepatol. 2017 Mar;14(3):141-142. doi: 10.1038/nrgastro.2017.7.
    note
    Source null
    related pmid
    28174418
    relationship
    Comment in
  5. citation
    Z Gastroenterol. 2017 Jul;55(7):685-686. doi: 10.1055/s-0043-106861.
    note
    Source null
    related pmid
    28437801
    relationship
    Comment in
  6. citation
    Dig Liver Dis. 2017 Aug;49(8):943-944. doi: 10.1016/j.dld.2017.04.022.
    note
    Source null
    related pmid
    28546063
    relationship
    Comment in
outcomes validated
false
pmid
27932229
provenance
batch id
7a1288ac8bb5f9826304
provider
NCBI PubMed ESummary
record sha256
5e0fc7659c59e6952cfa26337c7511c2664cd62414c9965dd5907d3b828af352
response sha256
0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
retrieved at
2026-09-09T23:47:23.138359+00:00
publication date
display
2017 Jan 7
precision
day
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27932229/
title
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice